ID29437A - Kombinasi dari formoterol dan flutikason propionat untuk asma - Google Patents

Kombinasi dari formoterol dan flutikason propionat untuk asma

Info

Publication number
ID29437A
ID29437A IDW00200101675A ID20011675A ID29437A ID 29437 A ID29437 A ID 29437A ID W00200101675 A IDW00200101675 A ID W00200101675A ID 20011675 A ID20011675 A ID 20011675A ID 29437 A ID29437 A ID 29437A
Authority
ID
Indonesia
Prior art keywords
flutikason
asma
formoterol
propionate
combinations
Prior art date
Application number
IDW00200101675A
Other languages
English (en)
Inventor
J G Clarke
H L Danahay
I F Hassan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29437(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID29437A publication Critical patent/ID29437A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW00200101675A 1999-02-18 2000-02-16 Kombinasi dari formoterol dan flutikason propionat untuk asma ID29437A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903759.0A GB9903759D0 (en) 1999-02-18 1999-02-18 Organic compounds

Publications (1)

Publication Number Publication Date
ID29437A true ID29437A (id) 2001-08-30

Family

ID=10848051

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101675A ID29437A (id) 1999-02-18 2000-02-16 Kombinasi dari formoterol dan flutikason propionat untuk asma

Country Status (31)

Country Link
US (4) US20020103260A1 (id)
EP (1) EP1152753B1 (id)
JP (1) JP2002537249A (id)
KR (2) KR20010102205A (id)
CN (1) CN1339965A (id)
AR (1) AR022609A1 (id)
AT (1) ATE266393T1 (id)
AU (1) AU758999B2 (id)
BR (1) BR0008276A (id)
CA (1) CA2368537A1 (id)
CO (1) CO5140098A1 (id)
CZ (1) CZ20012976A3 (id)
DE (1) DE60010662T2 (id)
DK (1) DK1152753T3 (id)
ES (1) ES2220411T3 (id)
GB (1) GB9903759D0 (id)
HU (1) HUP0200852A3 (id)
ID (1) ID29437A (id)
IL (1) IL144061A (id)
MY (1) MY126768A (id)
NO (1) NO20013987D0 (id)
NZ (1) NZ513526A (id)
PE (1) PE20001545A1 (id)
PL (1) PL349856A1 (id)
PT (1) PT1152753E (id)
RU (1) RU2249454C2 (id)
SK (1) SK11842001A3 (id)
TR (1) TR200102110T2 (id)
TW (1) TWI229601B (id)
WO (1) WO2000048587A1 (id)
ZA (1) ZA200105391B (id)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB2388843B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
GB2392915B (en) * 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005523268A (ja) 2002-02-04 2005-08-04 グラクソ グループ リミテッド グルココルチコイドおよびβ2−アドレナリン受容体アゴニストを含む吸入用製剤
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
RU2431501C2 (ru) * 2005-07-14 2011-10-20 Липотера, Инк. Липолитические составы с пролонгированным высвобождением для локального лечения отложения жировых тканей
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
KR20140025308A (ko) * 2010-10-12 2014-03-04 시플라 리미티드 약학 조성물
MX2013013440A (es) * 2011-05-17 2014-06-05 Pearl Therapeutics Inc Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
KR20150002774A (ko) * 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující

Also Published As

Publication number Publication date
IL144061A0 (en) 2002-04-21
DK1152753T3 (da) 2004-08-16
MY126768A (en) 2006-10-31
CN1339965A (zh) 2002-03-13
EP1152753A1 (en) 2001-11-14
PE20001545A1 (es) 2001-01-29
KR20010102205A (ko) 2001-11-15
HUP0200852A3 (en) 2004-04-28
NO20013987L (no) 2001-08-16
DE60010662D1 (de) 2004-06-17
ES2220411T3 (es) 2004-12-16
US20050287079A1 (en) 2005-12-29
US20020103260A1 (en) 2002-08-01
EP1152753B1 (en) 2004-05-12
NZ513526A (en) 2004-01-30
BR0008276A (pt) 2001-11-06
JP2002537249A (ja) 2002-11-05
US20100034890A1 (en) 2010-02-11
GB9903759D0 (en) 1999-04-14
CO5140098A1 (es) 2002-03-22
IL144061A (en) 2005-12-18
US20040101487A1 (en) 2004-05-27
AR022609A1 (es) 2002-09-04
DE60010662T2 (de) 2005-05-19
NO20013987D0 (no) 2001-08-16
AU758999B2 (en) 2003-04-03
CZ20012976A3 (cs) 2001-11-14
TWI229601B (en) 2005-03-21
ATE266393T1 (de) 2004-05-15
HK1042429A1 (en) 2002-08-16
TR200102110T2 (tr) 2001-10-22
PL349856A1 (en) 2002-09-23
CA2368537A1 (en) 2000-08-24
AU2911500A (en) 2000-09-04
RU2249454C2 (ru) 2005-04-10
ZA200105391B (en) 2002-06-21
SK11842001A3 (sk) 2001-12-03
HUP0200852A2 (en) 2002-08-28
KR20070104955A (ko) 2007-10-29
WO2000048587A1 (en) 2000-08-24
PT1152753E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
ID29437A (id) Kombinasi dari formoterol dan flutikason propionat untuk asma
ID27922A (id) KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
ID23673A (id) Formulasi farmasi yang terdiri dari amoksicilin dan klavulanat
EE200000145A (et) Budesoniidi ja formoterooli uus kasutamine
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
ID29457A (id) Turunan dan analog asam 3-aril propionat
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
PT1238161E (pt) Fabrico de papel e papelao
ID24962A (id) Turunan-turunan sulfonamida sebagai bakal obat dari
DE69822346D1 (de) Flüssigkeitsverpackung
PT1066027E (pt) Composicao farmaceutica de topiramato
ID29061A (id) METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53
ID27480A (id) Pembungkusan berstruktur dan elemennya
DE50015396D1 (de) Dynamische dichtung
GB0005199D0 (en) Modulation of histone deacetylase
FR2834043B1 (fr) Ensemble de serrage perfectionne et coupleur hydraulique le comportant
PT1228273E (pt) Fabrico de papel e papelao
PT1242685E (pt) Fabrico de papel e papelao
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
ID26955A (id) Komposisi farmasi homogen yang terdiri dari abacavir, lamivudin dan zidovudin
DE60107990D1 (de) Foliebehandlungsvorrichtung und Umwickelvorrichtung
NO20011491D0 (no) Reduksjon av oksidative stress faktorer
PL365582A1 (en) Use of salmeterol and fluticasone propionate combination
ID27980A (id) Coklat berisi-gas dan produksinya
DE69913452D1 (de) Drehmomentwandler und dessen Dichtungsanordnung